Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma

4 vistas
administrator
administrator
08/09/23

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).

  • categoría

Mostrar más

0 Comentarios Ordenar por

No se encontraron comentarios

Comentarios de Facebook

Hasta la próxima